My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC - Episode 3

Testing Methodologies and Standards in Metastatic NSCLC

,

Panelists discuss the various tests available for detecting genetic mutations in advanced non–small cell lung cancer (NSCLC), including next-generation sequencing (NGS), reverse transcription polymerase chain reaction (RT-PCR), fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), and Sanger sequencing, and explore whether one method is considered the “gold standard” according to the NCCN guidelines. They also address the appropriate use of circulating tumor DNA (ctDNA) testing, comparing it to tissue testing in this disease state.

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing
EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy
Now Viewing
EP. 3: Testing Methodologies and Standards in Metastatic NSCLC
EP. 4: Practical Considerations in Metastatic NSCLC: Access and Timing of Testing
  1. Dr Sands to Dr Wakelee: What tests are available for detecting genetic mutations (ie, NGS, RT-PCR, FISH, IHC, Sanger, etc) in advanced NSCLC?
  2. Is one considered the “gold standard” or preferred compared with the others?
  3. NCCN Guidelines Version 10.2024 Non-Small Cell Lung Cancer
  4. Dr. Wakelee: Describe when circulating tumor DNA (ctDNA) testing is appropriate.
  5. How does it compare to tissue testing in this disease state?